CEPI awards IDT Biologika up to $36M for MERS research by Eric Sagonowsky Tuesday, August 21, 2018 Right on the heels of last week's deal in Lassa fever, CEPI has awarded IDT Biologika up to $36 million for MERS research.
Profectus, Emergent win $36M deal for Lassa vaccine by Angus Liu Monday, August 20, 2018 Profectus’ Lassa candidate is based on its VesiculoVax vaccine delivery platform, which uses vesicular stomatitis virus as vector.
Inovio and GeneOne's MERS vaccine shows promise in phase 1 by Angus Liu Tuesday, July 3, 2018 Inovio's South Korean partner GeneOne plans to start a phase 1/2 study in South Korea in the third quarter.
Profectus, Emergent to work on Nipah vaccine under $25M CEPI deal by Angus Liu Friday, May 25, 2018 With MERS and Lassa fever projects funded, the outbreak-focused alliance is ready to put a check mark beside the third disease on its priority list.
CEPI signs $54.9M Lassa vaccine deal with HIV organization by Angus Liu Tuesday, May 22, 2018 The International AIDS Vaccine Initiative will use grant funding to develop a Lassa vaccine based on the VSV vector.
Inovio nets $56M CEPI grant for Lassa fever and MERS vaccines by Angus Liu Wednesday, April 11, 2018 The five-year grant will support Inovio through phase 2 development of DNA vaccines against Lassa fever and MERS.
CEPI grants Themis $37.5M for Lassa and MERS vaccines by Angus Liu Tuesday, March 6, 2018 The public-private vaccine coalition will support Themis' development of Lassa fever and MERS vaccines through phase 2.
Pharma joins in $1B outbreak prep group by Eric Sagonowsky Friday, January 20, 2017 Drugmakers have joined with governments and nonprofits around the world to launch an alliance that’ll take a proactive approach to potential deadly outbreaks.
